FDA Grants Orphan Drug Designation to HCB101 in HER2+/– Gastric Cancer
An orphan drug designation has been granted to HCB101 by the FDA to help combat HER2+/– gastric cancer.
FDA Issues Partial Clinical Hold on Lorigerlimab Trial in Gynecologic Cancers
The FDA decided to institute a partial clinical hold on the trial of Lorigerlimab, which is aimed at treating gynecologic cancers.
Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma
Efforts are in progress to refine the management of side effects from immune-checkpoint inhibitor therapies in patients suffering from melanoma.
FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma
The FDA granted fast-track designation to SRN-101, an AAV-based immuno-gene therapy, aimed at treating recurrent high-grade glioma.
Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma
A novel small molecule demonstrates promising early results in the treatment of pretreated multiple myelomas.
Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC
A comparison of outcomes for proton and photon therapies treating oropharyngeal cancer shows differences in immune preservation and long-term adverse effects.
